 Barclays downgraded shares of Eidos Therapeutics NASDAQ:EIDX from an equal weight rating to an underweight rating in a research report sent to investors on Tuesday, 247 WallStreet reports. The brokerage currently has 45.00 target price on the stock. Several other equities analysts also recently issued reports on EIDX. Roth Capital upped their target price on ... 